propafenone

(redirected from Rythmol sr)

propafenone

 [pro″pah-fe´nōn]
a sodium channel blocking agent that acts on the Purkinje fibers and the myocardium; used as the hydrochloride salt in treatment of life-threatening arrhythmias, administered orally.
Miller-Keane Encyclopedia and Dictionary of Medicine, Nursing, and Allied Health, Seventh Edition. © 2003 by Saunders, an imprint of Elsevier, Inc. All rights reserved.

propafenone

Rythmol® Cardiology A beta-blocking antiarrhythmic for severe ventricular and supraventricular arrhythmias–A Fib, V Tach, conduction block, HTN Complications Ventricular proarrhythmia; conduction defects Adverse effects Neurologic–headache, dizziness, paresthesias, peripheral neuropathy, GI–eg, N&V, anorexia. See Antiarrhythmic, Beta-blockers.
McGraw-Hill Concise Dictionary of Modern Medicine. © 2002 by The McGraw-Hill Companies, Inc.

propafenone

A drug used to treat heart irregularities (arrhythmias). A brand name is Arythmol.
Collins Dictionary of Medicine © Robert M. Youngson 2004, 2005
References in periodicals archive ?
M2 EQUITYBITES-September 11, 2017-Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR
India-based Glenmark Pharmaceuticals (NSE: GLENMARK) has been granted final approval by the US health regulator to market its generic version of Rythmol SR capsules, the company confirmed on Monday.
M2 PHARMA-September 11, 2017-Glenmark Pharmaceuticals granted final FDA approval to market generic version of Rythmol SR
On January 3, 2011, Par Pharmaceutical successfully launched the 225mg, 325mg, and 425mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline's Rythmol SR [R] .
Linde predicted that if the new REVERSE findings are confirmed in the much larger ongoing Automatic Defibrillator Implantation With Cardiac Resynchronization Therapy (MADIT-CRT) trial and Rythmol SR Atrial Fibrillation Trial (RAFT), as she expects, the indications for CRT will broaden to incorporate the large population of patients with class I and II heart failure.
for infringement of United States Patent 5,681,588, which expires in 2014 and relates to Reliant's Rythmol SR product.
That would be 900 mg for propafenone immediate release (IR), available generically; 850 mg for the sustained-release formulation (Rythmol SR); and 400 mg for flecainide (Tambocor).
The company added that Propafenone Hydrochloride Extended-Release Capsules USP, 225 mg, 325 mg, 425 mg is the generic version of GlaxoSmithKline's Rythmol SR.
145 GlaxoSmithKline Rythmol SR 00173078801 $39,321,455
Ernest Mario, Reliant's Chairman and Chief Executive Officer noted, "Our acquisition of the Rythmol product family, particularly the recently approved Rythmol SR (propafenone HCl extended release) dosage form, represents a significant expansion of Reliant's cardiovascular product franchise.
is shipping the 225-mg, 325-mg and 425-mg strengths of propafenone SR capsules, the generic version of GlaxoSmithKline PLC's Rythmol SR. Par points out that it has been awarded 180 days of marketing exclusivity (commencing at launch) for being the first to file an abbreviated new drug application (ANDA) containing a paragraph IV certification for the product.
The company said the propafenone SR capsules are the generic version of GlaxoSmithKline's Rythmol SR.